Ender 3 - extruder stepper skipping

paythelady.61 shared this article with you from Inoreader Ender 3 - extruder stepper skipping Via Recent Questions - 3D Printing Stack Exchange I have a problem most likely very similar to some reported by other users: extruder stepper is visually skipping a step from time to time. It rapidly rotates in the direction opposite to the one it is supposed to rotate. I noticed the following: The extruder stepper jumps totally randomly - there is nothing specific in the pattern printed, position etc. Stepper jumps more often on the infill, rarely on the walls. Details about print: PLA (Devil Design - various colors, they doesn't matter) Filament guide installed on top, but not yet before the extruder (it is printing right now, I'm waiting for the ball bearings too) Filament mounted on the top - in the place defined by Creality Extruder is already replaced with the aluminium one The mainboard is SKR E3 mini V2 (replaced recently) 95% flow set in Cura Printing on glass, leveled bed (the jumping occurs on all layers, not only first) 215 °C hotend temperature, 60 °C bed temperature Stepper motor current settings (from Merlin menu): 580 for X, Y & Z, 650 for E1 Other observations: What's interesting is that extruder motor jumps even if I manually unwind some filament, so that the only force that it has to overcome is only pushing filament into the head. I did a quick DIY wooden spool holder, so that the filament was fed almost horizontally. This actually seemed to make things worse - stepper jumped more often. I moved spool to the top again and it reduced jumping a little. Prints are done beatifully (after changing the motherboard, that is) - no lost lines or layers, walls connected with infill, perfect first layer etc. What may be the cause of stepper motor jumping? How can I solve it? Does it pose a threat to the motor or stepper? I need to print filament guide and spool holder with ball bearings, so that I can minimize force required by the extruder motor, but then the stepper will probably jump during the prints. I already damaged the original mainboard because of stuck filament, I don't want to destroy another one. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma

paythelady.61 shared this article with you from Inoreader Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma Via Latest Results for Investigational New Drugs Summary Background Precision medicine and drug repurposing are attractive strategies, especially for tumors with worse prognosis. Glioblastoma is a highly malignant brain tumor with limited treatment options and short survival times. We identified novel BRAF (47-438del) and PIK3R1 (G376R) mutations in a glioblastoma patient by RNA-sequencing. Methods The protein expression of BRAF and PIK3R1 as well as the lack of EGFR expression as analyzed by immunohistochemistry corroborated RNA-sequencing data. The expression of additional markers (AKT, SRC, mTOR, NF-κB, Ki-67) emphasized the aggressiveness of the tumor. Then, we screened a chemical library of > 1500 FDA-approved drugs and > 25,000 novel compounds in the ZINC database to find established drugs targeting BRAF47-438del and PIK3R1-G376R mutated proteins. Results Several compounds (including anthracyclines) bound with higher affinities than the control drugs (sorafenib and vemurafenib for BRAF and PI-103 and LY-294,002 for PIK3R1). Subsequent cytotoxicity analyses showed that anthracyclines might be suitable drug candidates. Aclarubicin revealed higher cytotoxicity than both sorafenib and vemurafenib, whereas idarubicin and daunorubicin revealed higher cytotoxicity than LY-294,002. Liposomal formulations of anthracyclines may be suitable to cross the blood brain barrier. Conclusions In conclusion, we identified novel small molecules via a drug repurposing approach that could be effectively used for personalized glioblastoma therapy especially for patients carrying BRAF47-438del and PIK3R1-G376R mutations. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Prognostic Significance of Pain in Parotid Gland Malignancy

paythelady.61 shared this article with you from Inoreader Prognostic Significance of Pain in Parotid Gland Malignancy Via The Laryngoscope Objectives/Hypothesis To better understand the significance of pain as a predictor of disease severity in parotid gland malignancy. Study Design A retrospective chart review of patients treated for primary parotid gland malignancy at our institution between 1991 and 2020 was performed. Methods Patient records were retrospectively reviewed and relevant clinical parameters were collected. Patients were stratified into low stage (I and II) disease and high stage (III and IV) disease groups to analyze the independent effect of pain at initial presentation on disease recurrence rate and disease‐free survival using Kaplan–Meier survival curves and an independent two‐sample t‐test. Results Of 154 patients evaluated, there were 69 patients in the low stage group and 80 patients in the high stage group. Thirty‐seven high stage patients presented with pain. High stage patients with pain were significantly more likely to develop disease recurrence than high stage patients without pain (58.5% [22/37] versus 33.3% [13/39], P = .022). High stage patients with pain also had significantly decreased disease‐free survival time compared to high stage patients without pain (P = .027). Conclusion Pain on presentation appears to be a poor prognostic factor for patients with parotid gland malignancy. For patients with demonstrated high stage disease, pain is independently associated with increased risk of recurrence and decreased disease‐free survival time. Level of Evidence 4 Laryngoscope, 2020 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Oil pulling to relieve medication‐induced xerostomia: a randomized, single‐blind, crossover trial

paythelady.61 shared this article with you from Inoreader Oil pulling to relieve medication‐induced xerostomia: a randomized, single‐blind, crossover trial Via Oral Diseases Abstract Objectives To determine the subjective effectiveness of oilpulling on medication‐induced xerostomia with regard to symptom‐relief, quality of life, taste, mucosal moisture and oral parameters. Materials and methods In a randomized, single‐blind, crossover trial in participants with medication‐induced xerostomia (n=26; mean age 64.71 (standard deviation (SD) 15.60) years), we investigated oilpulling efficacy (sunflower oil) versus mineral water after one‐week use. Xerostomic burden (visual analogue scale, VAS), symptom‐relief and oral examinations (gingivitis‐index, plaque‐index, whole stimulated and unstimulated salivation rates) were investigated at baseline and the end of the follow‐up. Results Oilpulling reduced the xerostomic burden (baseline value 6.46 (SD 1.80), decreasing to 4.93 (SD 2.97)) (p=0.003), without difference between oil versus water (p=0.067). Baseline values for water were 6.08 (SD 2.17) decreasing to 5.72 (SD 2.17) (p=0.124). Compared to water, oil made swallowing easier (p=0.031), caused a pleasant mouthfeel (p=0.031) and caused less waking up at night (p=0.031). Effectiveness (p=0.002) and duration (p=0.007) of symptom‐relief showed differences between products in favour of oil. Conclusions Oil pulling alleviated the overall xerostomic burden. In the comparison between oil and water, no difference regarding symptom‐relief could be shown. Patients should be informed of possibilities and limitations of oilpulling as inexpensive and easy‐to‐obtain alternative to commercially‐available products for short‐term symptom‐relief. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

In‐depth analysis of thyroid cancer mortality

paythelady.61 shared this article with you from Inoreader In‐depth analysis of thyroid cancer mortality Via Head & Neck Abstract Background There are reports of an increasing thyroid cancer mortality rate. This study aimed to analyze the latest trends in this rate over time and compare findings from different cancer registries. Methods Thyroid cancer incidence‐based mortality (IBM) rates were obtained from the Surveillance, Epidemiology, and End Results (SEER) program, including SEER‐9, SEER‐13, and SEER‐18. The National Center for Health Statistics (NCHS) thyroid cancer mortality rate was acquired for comparison. Statistical analysis was performed using the JoinPoint software. Results NCHS data revealed an overall annual percent change (APC) over 1987 to 2017 of 0.61 (P < .01), and the value was nearly four times greater for males compared to females. The overall IBM APC values for SEER‐9, SEER‐13, and SEER‐18 were also positive and statistically significant (P < .01). Conclusions The increased thyroid cancer mortality rate observed in previous studies continues to be statistically significant based on updated NCHS and SEER IBM data. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Definitive intensity‐modulated radiotherapy or surgery for early oral cavity squamous cell carcinoma: Propensity‐score‐matched, nationwide, population‐based cohort study

paythelady.61 shared this article with you from Inoreader Definitive intensity‐modulated radiotherapy or surgery for early oral cavity squamous cell carcinoma: Propensity‐score‐matched, nationwide, population‐based cohort study Via Head & Neck Abstract Background No evidence is currently available to estimate the outcomes of intensity‐modulated radiation therapy (IMRT) and surgery for patients with early oral cavity squamous cell carcinoma (E‐OCSCC). Methods We recruited patients from the Taiwan Cancer Registry Database who had received a diagnosis of E‐OCSCC. Propensity score matching was performed, and Cox proportional hazards model was used to analyze all‐cause mortality. Results In the multivariate Cox regression analyses, the adjusted hazard ratio (aHR) (95% confidence interval [CI]) for surgery compared with definitive IMRT, T2N0M0 compared with T1N0M0, and male patients compared with female patients were 0.303 (0.245, 0.375), 1.340 (1.077, 1.668), and 2.012 (1.432, 2.826), respectively. The aHRs (95% CIs) for age 61 to 70, 71 to 80, and ≧81 years compared with <40 years were 2.984 (1.43, 4.225), 3.353 (2.578, 4.112), and 4.277 (4.104, 5.679), respectively. Conclusions For patients with E‐OCSCC, surgery may be considered the first option rather than definitive IMRT. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

primary salivary gland tumors in pediatric

paythelady.61 shared this article with you from Inoreader Clinicopathological analysis and survival outcomes of primary salivary gland tumors in pediatric patients: a systematic review Via Journal of Oral Pathology & Medicine Abstract Background Salivary gland tumors are a diverse group of uncommon neoplasms that are rare in pediatric patients. The aim of this study was to evaluate the clinicopathological profile and survival outcomes of pediatric patients affected by salivary gland tumors. Materials and methods An extensive search was carried out using the MEDLINE/PubMed, EMBASE, Scopus databases, and grey literature. The risk of bias was available in all papers included. Results A total of 2,830 articles were initially retrieved with 54 remaining for data extraction, resulting in 2,937 cases. This comprised forty‐five case series' and nine cohort studies. These tumors were slightly more prevalent in females (57.4%). The patients' age ranged from 0.3 to 19 years old, with a mean age of 13.3 years. Parotid was the most affected site (81.9%), and 99.2% of cases clinically exhibited a swelling. Presence of pain/tenderness was reported in 13.5% of the cases, with an average duration of 12.6 months for the appearance of symptoms. Most of the reported cases were malignant tumors (75.4%), with mucoepidermoid carcinoma the most common tumor of all tumors (44.8%), followed by pleomorphic adenoma (24.1%). Surgery alone was the leading treatment choice in 74.9% cases and the 5‐year overall survival rate of patients was 93.1%. Patients with symptoms (P =0.001), local recurrence (P <0.001), metastasis (P <0.001), and those not undergoin g surgery or surgery combined with radiotherapy (P <0.001) showed lower survival rates. Conclusion The pediatric patients present a high frequency of malignant salivary neoplasms and a high overall survival rate. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

A novel temporal‐predominant neuro‐astroglial tauopathy associated with TMEM106B gene polymorphism in FTLD/ALS‐TDP

paythelady.61 shared this article with you from Inoreader A novel temporal‐predominant neuro‐astroglial tauopathy associated with TMEM106B gene polymorphism in FTLD/ALS‐TDP Via Brain Pathology Abstract Background Polymorphisms in TMEM106B, a gene on chromosome 7p21.3 involved in lysosomal trafficking, correlates to worse neuropathological and clinical outcomes in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) with TDP‐43 inclusions. In a small cohort of C9orf72 expansion carriers, we previously found an atypical, neuroglial tauopathy in cases harboring a TMEM106B rs1990622 A/A genotype. Aims To test whether TMEM106B genotype affects the risk of developing atypical tauopathy under a recessive genotype model (presence versus absence of two major alleles: A/A vs. A/G and G/G). Methods We characterized the atypical tauopathy neuropathologically and determined its frequency by TMEM106B rs1990622 genotypes in 90 postmortem cases with a primary diagnosis of FTLD/ALS‐TDP [mean age at death 65.5 years (±8.1),40% female]. We investigated the effect of this new atypical tauopathy on demographics and clinical and neuropsychological metrics. We also genotyped TMEM106B in an independent series with phenotypically similar cases. Results Sixteen cases (16/90, 17.7 %) showed the temporal‐predominant neuro‐astroglial tauopathy, and 93.7% of them carried an A/A genotype (vs. ~35% in a population cohort). The odds ratio of FTLD/ALS‐TDP individuals with the A/A genotype showing neuro‐astroglial tauopathy was 13.9. Individuals with this tauopathy were older at onset (p=0.01). The validation cohort had a similarly high proportion of rs1990622 A/A genotype. TDP‐43 and tau changes co‐occur in a subset of neurons. Conclusions Our data add to the growing body of evidence that TMEM106B polymorphisms may modulate neurodegeneration. A distinctive medial temporal predominant, 4‐repeat, neuro‐astroglial tauopathy strongly correlates to TMEM106B A/A genotype in FTLD/ALS‐TDP cases. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Advanced age heightens hepatic damage in a murine model of scald burn injury

paythelady.61 shared this article with you from Inoreader Advanced age heightens hepatic damage in a murine model of scald burn injury Via Journal of Trauma and Acute Care Surgery - Published Ahead-of-Print Background: Elderly burn patients exhibit a lower survival rate compared with younger counterparts. The liver is susceptible to damage after burn injury, which predisposes to poor outcomes. Lipid homeostasis and the antioxidant glutathione system play fundamental roles in preserving liver integrity. Herein, we explored changes in these major pathways associated with liver damage in the aging animals after burn injury. Methods: We compared liver enzymes, histology, lipid-peroxidation, and glutathione-metabolism profiles from young and aged female mice after a 15% total-body-surface-area burn. Mice were euthanized at 24hours after injury, and livers and serum were collected. Results: Aged burn animals exhibited elevated (p View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Fast Track Pathway Provides Safe, Value Based Care on Busy Acute Care Surgery Service

paythelady.61 shared this article with you from Inoreader Fast Track Pathway Provides Safe, Value Based Care on Busy Acute Care Surgery Service Via Journal of Trauma and Acute Care Surgery - Published Ahead-of-Print Abstract: Background Fast track(FT) pathways have been adopted across a multitude of elective surgeries but have been slow to be adopted into the acute care surgery(ACS) realm. We hypothesized that a FT pathway for acute cholecystitis patients would decrease patient length of stay and resource utilization. Methods All patients at two hospitals, one with a FT pathway and one with a traditional pathway, that underwent an urgent laparoscopic cholecystectomy for acute cholecystitis between May 1, 2019 and October 31, 2019 were queried using CPT codes. Exclusion criteria were conversion to open or partial cholecystectomy. Retrospective chart review was used to gather demographics, operative, hospital course, and outcomes. Time to OR, hospital length of stay, and resource utilization were the primary outcomes. Results There was a total of 479 urgent laparoscopic cholecystectomies performed, four hundred and thirty(89.8%) were performed under the FT pathway. The median[IQR] time to the OR was not different: 14.1 hours[8.3-29.0 hours] for FT and 18.5 hours[11.9-25.9 hours] for traditional(p=0.316). However, the median length of stay was shorter by 15.9 hours in the FT cohort(22.6 hours, [14.2-40.4] vs 38.5 hours,[28.3-56.3];p0.2 for all). On multivariate analysis, having a fast track pathway was an independent predictor of discharge within 24 hours of surgical consultation(OR 7.65, 95% CI 2.90-20.15, p View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

TRAUMA PATIENT TRANSPORT TIMES UNCHANGED DESPITE TRAUMA CENTER PROLIFERATION: A 10 YEAR REVIEW

paythelady.61 shared this article with you from Inoreader TRAUMA PATIENT TRANSPORT TIMES UNCHANGED DESPITE TRAUMA CENTER PROLIFERATION: A 10 YEAR REVIEW Via Journal of Trauma and Acute Care Surgery - Published Ahead-of-Print Introduction In certain regions of the U.S. there has been a dramatic proliferation of trauma centers. The goal of our study was to evaluate transport times during this period of trauma center proliferation. Methods Aggregated data summarizing level I trauma center admissions in Arizona between 2009 and 2018 were provided to our institution by the Arizona Department of Health Services. We evaluated patient demographics, transport times and injury severity for both rural and urban injuries. Results Data included statistics summarizing 266,605 level I trauma admissions in the state of Arizona. The number of state-designated trauma centers during this time increased from 14 to 47, with level I centers increasing from 8 to 13. Slight decreases in mean ISS (rural 9.4 vs. 8.4; urban 7.9 vs 7.0) were observed over this period. Median transport time for cases transported from the injury scene directly to a level I center remained stable in urban areas at 0.9 hours in both 2009 and 2018. In rural areas, transport times for these cases were approximately double, but also stable, with median times of 1.8 and 1.9 hours. Transport times for cases requiring inter-facility transfer prior to admission at a level I center increased by 0.3 hours for urban injuries (5.3 hours to 5.6) and 0.9 hours for rural injuries (5.6 to 6.5). Conclusion Despite the 3-fold increase in the number of state-designated trauma centers, transport time has not decreased in urban or rural areas. This finding highlights the need for regulatory oversight regarding the number and geographic placement of state-designated trauma centers. Level of Evidence III The authors declare no conflicts of interest. The study was presented as a Quickshot at the 79th Annual Meeting of AAST & Clinical Congress of Acute Care Surgery held online instead of Waikoloa, Hawaii, September 9-12, 2020. Corresponding Author: Jordan A. Weinberg, MD, Division Chief, Trauma/Acute General Surgery, Trauma Administration, St. Joseph's Hospital and Medical Center, 350 W. Thomas Road, Phoenix, AZ 85013. Tel: (602) 406-3157. Email: JordanWeinberg@Creighton.edu © 2020 Lippincott Williams & Wilkins, Inc. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Provisional Minifragment Plate Fixation of Acetabular Fractures—A Technical Trick

paythelady.61 shared this article with you from Inoreader Provisional Minifragment Plate Fixation of Acetabular Fractures—A Technical Trick Via Journal of Orthopaedic Trauma - Most Popular Articles Summary: Acetabular fractures may not always be amenable to classic clamp-assisted reductions and interfragmentary lag screw fixation. The routine clamp-assisted reductions with limited osseous territory availability can inhibit typical 3.5-mm reconstruction plate application. Provisional minifragment plate fixation of these fracture patterns with subsequent clamp removal allows for definitive plate application. The provisional minifragment plates may also be retained to theoretically augment fixation. The authors present a step-by-step technique and clinical series of 57 patients demonstrating provisional minifragment fixation of elementary (n = 8) and associated (n = 49) acetabular fractures. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.